Summary of Zymeworks Conference Call Company Overview - **Company**: Zymeworks (NasdaqGS: ZYME) - **Focus**: Specializes in antibody-drug conjugates (ADCs), T-cell engagers, and protein engineering - **Key Product**: Zanya, licensed to Jazz Pharmaceuticals, has shown positive results in phase 3 clinical trials for gastric cancer [5][6] Core Strategies and Financials - **R&D Focus**: Zymeworks is evolving to concentrate on research and development (R&D) and partnerships rather than commercialization of drugs [7][11] - **Capital Deployment**: The company has access to over $440 million in near-term milestones and high teen digit royalties from Jazz, which will be strategically deployed across three areas: internal pipeline, asset aggregation, and stock buybacks [12][15] - **Stock Buyback**: Authorized $120 million in stock buybacks, with $62 million already implemented [15] Clinical Developments - **Zanya's Clinical Success**: Positive progression-free survival (PFS) of around 12 months in gastric cancer, with safety data indicating low rates of discontinuation due to adverse effects [34][35] - **Future Approval**: Anticipated approval for Zanya in the U.S. in the latter half of 2026 [35] Partnerships and Licensing - **Royalty Pharma Deal**: Zymeworks entered a $250 million debt financing deal with Royalty Pharma, retaining 70% of royalties until the debt is repaid, allowing for low-cost capital access [21][46] - **Janssen Collaboration**: The KLK2 T-cell engager licensed to J&J is undergoing three registration trials, indicating strong interest and potential for future growth in prostate cancer treatment [57][58] Pipeline and Future Directions - **ADC Strategy**: Zymeworks has two ADC assets in clinical trials, focusing on unique antibody designs and payloads to enhance therapeutic windows [49][51] - **Upcoming Trials**: Plans to advance a DLL3-targeted T-cell engager and an IL-4/IL-33 combination for COPD and asthma into clinical trials by late 2026 [53][54] - **Preclinical Developments**: Ongoing work on a RAS ADC and other T-cell engagers, with data expected later this year [54] Market Position and Competitive Landscape - **Competitive Edge**: Zymeworks aims to differentiate itself by leveraging internal R&D capabilities to enhance the success of acquired assets, unlike traditional royalty companies [17][18] - **Market Expectations**: Anticipated that Zanya will replace existing treatments like Herceptin in gastric cancer, with ongoing evaluations in breast cancer trials showing promising early interest [36][40][44] Conclusion - Zymeworks is strategically positioned to leverage its successful clinical data and partnerships to enhance its pipeline and shareholder value, with a clear focus on R&D and innovative drug development strategies.

Context Therapeutics FY Conference Summary Company Overview - **Company Name**: Context Therapeutics (NasdaqCM:CNTX) - **Focus**: Development of T-cell engagers, a class of antibodies that enhance the immune system's ability to target cancer cells [2][3] Core Programs - **Programs**: - **CT-76 (Claudin 6)**: Targeting ovarian, endometrial, and testicular cancers, with a focus on ovarian [3][4] - **CT-95 (Mesothelin)**: Targeting pancreatic, ovarian, and mesothelioma cancers [3][21] - **CT-202 (Nectin-4)**: Targeting a broad range of tumors including triple-negative breast cancer, bladder cancer, and colorectal cancer [4][28] Clinical Development and Data Updates - **Claudin 6**: Phase I data expected in Q2 2026, aiming for 10-12 ovarian patients at target dose levels [4][34] - **Mesothelin**: Data expected mid-2026, with a focus on pancreatic and ovarian cancers [21][34] - **Nectin-4**: Anticipated to enter the clinic in Q2 2026, with a significant market opportunity [28][34] Mechanism of Action and Safety Profile - **T-cell Engagers**: Designed to bridge T-cells and cancer cells, enhancing immune response [2][10] - **Safety Considerations**: - High-affinity CD3 format believed to mitigate cytokine release syndrome (CRS) risks [6][20] - Claudin 6 shows low risk for CRS due to its expression only in cancer cells [13][14] - Mesothelin program employs a lower affinity binder to minimize lung toxicity [23][24] Market Position and Competitive Landscape - **Market Opportunity**: - Claudin 6 and mesothelin represent significant market opportunities due to their expression in various cancers [21][26] - Nectin-4 is highlighted as a top target for treatment-eligible patients [33] - **Competitive Analysis**: - Context Therapeutics differentiates itself from competitors like Xencor and Third Rock by focusing on high-affinity CD3 and a clean safety profile [19][20] Financial Position - **Funding**: Raised $115 million in 2025, providing sufficient cash flow through key inflection points in 2026 [34] Key Takeaways - Context Therapeutics is positioned at an exciting inflection point with multiple clinical updates expected in the near future, particularly in T-cell engagers targeting solid tumors. - The company emphasizes a strong safety profile and innovative mechanisms of action, which may provide a competitive edge in the oncology market. - The upcoming data releases are critical for assessing the efficacy and market potential of their pipeline programs.

Financial Data and Key Metrics Changes - The company reported a net loss of $438 million for 2025, a decrease from $522 million in 2024, reflecting improved financial performance [44] - R&D expenses decreased by 10% to $456 million in 2025 from $507 million in 2024, while SG&A expenses fell by 23% to $92 million from $119 million [44] - The company started 2026 with approximately $782 million in cash, cash equivalents, and investments, excluding the upfront cash and equity from the Astellas collaboration [45] Business Line Data and Key Metrics Changes - The strategic collaboration with Astellas focuses on the development and commercialization of VIR-5500, a T-cell engager for prostate cancer, which is expected to unlock significant market opportunities [7][14] - The collaboration includes a total potential of $1.7 billion in combined upfront and milestone payments, with a 50/50 profit-sharing arrangement in the U.S. [14][43] Market Data and Key Metrics Changes - Prostate cancer remains a significant global health burden, with 1 in 8 men diagnosed in their lifetime and a five-year survival rate of only 30% for patients with metastatic castration-resistant prostate cancer (mCRPC) [9] - The collaboration aims to address the substantial unmet need for novel solutions in prostate cancer treatment, particularly for patients with advanced disease [8][9] Company Strategy and Development Direction - The company aims to position VIR-5500 as a best-in-class T-cell engager, leveraging the PRO-XTEN platform to develop next-generation therapies for solid tumors [8][46] - Future development plans include late-line mCRPC monotherapy, combination therapies, and expansion into metastatic hormone-sensitive prostate cancer [39][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of VIR-5500 based on emerging safety and efficacy data, which supports the broader PRO-XTEN platform approach [8][39] - The collaboration with Astellas is expected to accelerate clinical development and broaden patient access to VIR-5500, enhancing the company's position in the oncology market [46][47] Other Important Information - The company plans to initiate dose expansion cohorts in the second quarter of 2026, focusing on various patient populations within the prostate cancer treatment paradigm [39][62] - The PRO-XTEN platform allows for rapid engineering of new T-cell engagers, creating a sustainable pipeline of differentiated therapies [46] Q&A Session Summary Question: Can you comment on the range of PSA responses seen by prior line of therapies, particularly with regard to prior radiotherapy? - Management noted strong PSA responses, especially at higher doses, with one patient showing a PSA 99 response after prior radioligand treatment [55][56] Question: What are the next steps before moving to phase 3, and are there plans to explore additional dosing schemes? - The company plans to enter expansion cohorts in Q2 2026, including late-line mCRPC and combination therapies, while also optimizing dosing to meet FDA requirements [61][62] Question: How will the collaboration with Astellas unlock resources for the broader PRO-XTEN platform? - The partnership is expected to leverage Astellas' capabilities to accelerate the VIR-5500 program and potentially benefit other programs within the PRO-XTEN platform [66] Question: Can you provide more information on the go-forward dose and any grade 3 CRS observed? - The go-forward dose is expected to be in the range of 3,000 to 3,500 micrograms per kilogram, with no grade 3 CRS observed at doses above 3,000 [79][80]

2026 Vir Biotechnology, Inc. 1 VIR-5500 Strategic Collaboration with Astellas and Positive Phase 1 Data February 23, 2026 2026 Vir Biotechnology, Inc. 2 Agenda Legal disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the therapeutic and commercial potential of VIR-5500 and other assets within its oncology solid tumor portfolio, precl ...

Summary of Cullinan Therapeutics Conference Call Company Overview - **Company**: Cullinan Therapeutics (NasdaqGS: CGEM) - **Date**: February 19, 2026 - **Event**: Citi's Virtual Oncology Leadership Summit Key Points Oncology Pipeline Development - **2026 Significance**: Cullinan Therapeutics anticipates multiple catalysts across its oncology pipeline, particularly for T-cell engagers CLN-978 and CLN-049 [6][72] - **CLN-978**: A CD19 by CD3 T-cell engager targeting autoimmune diseases with a global development program aimed at lupus, rheumatoid arthritis (RA), and Sjögren's disease. The molecule is noted for its high binding affinity and potential to replace monoclonal antibodies [7][8] - **CLN-049**: A FLT3 x CD3 T-cell engager for acute myeloid leukemia (AML), presenting a first-in-class opportunity. The company aims to transition from dose escalation to dose expansion and is utilizing Fast Track designation from the FDA to select a recommended phase II dose [9][11] Clinical Data and Efficacy - **CLN-049 Efficacy**: Presented compelling monotherapy efficacy data at ASH 2025, with a complete response rate of approximately 30% and durable responses observed in patients, including those with P53 mutations [20][41] - **Safety Profile**: The safety profile of CLN-049 is favorable, with a lower incidence of cytokine release syndrome (CRS) compared to other T-cell engagers [21][22] Market Opportunity - **AML Market Size**: Approximately 20,000 new AML cases annually in the US, with a significant relapse/refractory patient pool. The potential market for CLN-049 in this segment is estimated to be a billion-dollar opportunity, with further expansion into frontline settings potentially unlocking multi-billion dollar opportunities [57][58] Financial Position - **Cash Reserves**: As of December 2025, Cullinan reported over $430 million in cash, providing a runway into 2029 to support ongoing programs [15] Zipalertinib Development - **Partnership with Taiho**: Zipalertinib, an EGFR exon 20 tyrosine kinase inhibitor, is in collaboration with Taiho, which is completing a rolling NDA submission. The agreement includes a 50/50 profit share in the US and $130 million in regulatory milestones [12][61] - **Market Potential**: The annual diagnosis of exon 20 non-small cell lung cancer in the US is estimated at 3,000-5,000 patients, presenting a significant market opportunity [60] Future Milestones - **Upcoming Data Releases**: Data updates for CLN-049 are expected in the second half of 2026, with dose expansion cohorts planned for initiation in Q2 2026 [70][71] - **Regulatory Pathway**: The company is confident in pursuing accelerated approval pathways for both CLN-049 and zipalertinib, with clear development strategies outlined [46][48] Conclusion - **2026 Outlook**: Cullinan Therapeutics is positioned for a transformative year with multiple catalysts across its oncology and autoimmune pipelines, aiming to create shareholder value through strategic advancements and regulatory approvals [72]

CytomX Therapeutics Conference Call Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Focus**: Development of masked biologics technology, specifically targeting cancer therapies [2][3] Key Industry Insights - **Technology**: CytomX has pioneered the field of masked biologics, allowing for targeted drug delivery to tumor cells while minimizing effects on healthy tissues [2][3] - **Clinical Programs**: The company is currently focused on two clinical programs, with the lead program being a masked EpCAM antibody-drug conjugate (ADC) [3][4] Core Product Insights - **Lead Product**: CX-2051, a masked ADC targeting EpCAM, which is highly expressed in various solid tumors, particularly colorectal cancer (CRC) [5][6] - **Target Rationale**: EpCAM is a compelling target due to its high expression in solid tumors, but previous attempts to target it have faced toxicity issues. CytomX believes its masking technology can mitigate these toxicities [5][6][7] Clinical Data Highlights - **Colorectal Cancer Statistics**: CRC has 1.9 million cases globally and is the second leading cause of cancer death, with a five-year survival rate of only 13% in metastatic cases [12] - **Phase 1 Data**: In a difficult-to-treat patient population (average of four prior therapies), CX-2051 showed a 28% objective response rate and 94% disease control rate, with a progression-free survival (PFS) of 5.8 months [14][19] - **Safety Profile**: The drug did not exhibit classic EpCAM-related toxicities such as pancreatitis or liver toxicity. The main adverse effect observed was grade 3 diarrhea in 21% of patients [15][16] Future Development Plans - **Expansion of Clinical Trials**: CytomX plans to expand the enrollment to approximately 100 patients across three active doses (7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg) to better understand efficacy and safety [19][20] - **Regulatory Pathway**: The company aims to discuss potential registrational studies with the FDA by mid-2027, focusing on late-line CRC treatment [37][38] Competitive Landscape - **Market Position**: CytomX believes it has a strong competitive position in the ADC space for CRC, with a compelling drug profile compared to other ADCs targeting CRC [46][47] - **Other ADCs**: Competitors include Merck's CEACAM5 ADC and AbbVie's cMet ADC, but CytomX asserts that its drug has broader applicability due to the widespread expression of EpCAM [46][47] Combination Therapy Strategy - **Initial Combinations**: The company plans to start combination studies with bevacizumab and is considering other combinations to enhance treatment efficacy and expand market opportunities [49][50] - **Long-term Vision**: CytomX aims to replace traditional chemotherapy regimens, particularly irinotecan, with its ADC in earlier treatment lines [41][42] Additional Product Insights - **Other Asset**: CytomX is also developing a second product candidate, an interferon alpha-2b therapy for late-line melanoma, which is expected to be combined with KEYTRUDA [53] Conclusion - CytomX Therapeutics is positioned to address significant unmet needs in cancer treatment, particularly in CRC, with its innovative masked biologics technology and promising clinical data. The company is focused on expanding its clinical trials and exploring combination therapies to enhance treatment outcomes.